A Phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression≥1% and an STK11 co-mutation

被引：0

作者：

Lindsay, Colin R.

Tan, Daniel

Malhotra, Shweta

Caparica, Rafael

Boran, Aislyn D.

Castro, Gilberto

Glaser, Sabine

Veluswamy, Rajwanth R.

Felip, Enriqueta

机构：

来源：

CANCER RESEARCH | 2023年 / 83卷 / 08期

关键词：

D O I：

10.1158/1538-7445.AM2023-CT048

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT048

引用

页数：2

共 50 条

[1] A Phase II Trial of JDQ443 in KRAS G12C-Mutated NSCLC with PD-L1 Expression <1% or PD-L1 Expression ≥1% and an STK11 Co-Mutation
Lindsay, C.
Veluswamy, R.
Castro Junior, G.
Tan, D. Y. H.
Caparica, R.
Glaser, S.
Malhotra, S.
Felip, E.
Chan, E.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (01): : E13 - E14
[2] A phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation.
Lindsay, Colin R.
Veluswamy, Rajwanth
Castro, Gilberto
Tan, Daniel Shao-Weng
Caparica, Rafael
Glaser, Sabine
Malhotra, Shweta
Boran, Aislyn
Felip, Enriqueta
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[3] PD-L1 expression in pleomorphic lung carcinoma with STK11 mutations
Januszewski, A.
Zhang, Y. Z.
Chang, W. -C.
Laggner, U.
Bowman, A.
Adefila-Ideozu, T.
Nicholson, A.
Bowcock, A.
Popat, S.
LUNG CANCER, 2020, 139 : S58 - S58
[4] PD-L1 expression in NSCLC
Janzic, U.
Kern, I.
Janzic, A.
Cavka, L.
Cufer, T.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S59
[5] Association of STK11/LKB1 mutations with primary resistance to PD-1/PD-L1 axis blockade in PD-L1 positive nonsquamous NSCLC.
Skoulidis, Ferdinandos
Carter, Brett W.
Zhang, Jianjun
Wistuba, Ignacio Ivan
Papadimitrakopoulou, Vassiliki
Heymach, John
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
Monneur, Audrey
Goncalves, Anthony
Bertucci, Francois
BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
[7] PD-L1 expression in NSCLC and biopsy size
Kern, I.
Kovacevic, M.
Janzic, U.
Cufer, T.
VIRCHOWS ARCHIV, 2016, 469 : S127 - S127
[8] PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
Kojima, Kensuke
Sakamoto, Tetsuki
Kasai, Takahiko
Kagawa, Tomoko
Yoon, Hyungeun
Atagi, Shinji
SCIENTIFIC REPORTS, 2021, 11 (01)
[9] PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
Kensuke Kojima
Tetsuki Sakamoto
Takahiko Kasai
Tomoko Kagawa
Hyungeun Yoon
Shinji Atagi
Scientific Reports, 11
[10] Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy
Cefali, Marco
Epistolio, Samantha
Ramelli, Giulia
Mangan, Dylan
Molinari, Francesca
Martin, Vittoria
Freguia, Stefania
Mazzucchelli, Luca
Froesch, Patrizia
Frattini, Milo
Wannesson, Luciano
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (06)

← 1 2 3 4 5 →

A Phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression &lt;1% or PD-L1 expression≥1% and an STK11 co-mutation

A Phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression≥1% and an STK11 co-mutation